These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34690116)

  • 1. Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan.
    Hatano M; Takeuchi I; Yamashita K; Morita A; Tozawa K; Sakakibara T; Hajitsu G; Hanya M; Yamada S; Iwata N; Kamei H
    Clin Psychopharmacol Neurosci; 2021 Nov; 19(4):610-617. PubMed ID: 34690116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability.
    Singh SM; Haddad PM; Husain N; Heaney E; Tomenson B; Chaudhry IB
    Ther Adv Psychopharmacol; 2016 Jun; 6(3):162-71. PubMed ID: 27354904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.
    Das AK; Malik A; Haddad PM
    Ther Adv Psychopharmacol; 2014 Oct; 4(5):179-85. PubMed ID: 25360242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitude and preferences towards oral and long-acting injectable antipsychotics in patients with psychosis in KwaZulu-Natal, South Africa.
    Roopun KR; Tomita A; Paruk S
    S Afr J Psychiatr; 2020; 26():1509. PubMed ID: 32832130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
    Stanković Z; Ille T
    Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
    Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
    BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics.
    Mace S; Chak O; Punny S; Sedough-Abbasian D; Vegad C; Taylor DM
    Ther Adv Psychopharmacol; 2019; 9():2045125319860977. PubMed ID: 31321027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
    Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
    Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
    J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan.
    Sugawara N; Kudo S; Ishioka M; Sato Y; Kubo K; Yasui-Furukori N
    Neuropsychiatr Dis Treat; 2019; 15():205-211. PubMed ID: 30666117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic choice: understanding shared decision-making among doctors and patients.
    Yeo V; Dowsey M; Alguera-Lara V; Ride J; Lancsar E; Castle DJ
    J Ment Health; 2021 Feb; 30(1):66-73. PubMed ID: 31240989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.